
Kumar Prabhash, Mbbs,, Dm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1848821/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in <i>EGFR</i> -Mutated Lung Cancer. Journal of Clinical Oncology, 2020, 38, 124-136.	0.8	295
2	Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study. Journal of Thoracic Oncology, 2012, 7, 1823-1829.	0.5	281
3	Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. Journal of Clinical Oncology, 2018, 36, 1064-1072.	0.8	229
4	Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. Journal of Clinical Oncology, 2021, 39, 1234-1242.	0.8	178
5	Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. Oncologist, 2017, 22, 1056-1066.	1.9	122
6	Crizotinib: A comprehensive review. South Asian Journal of Cancer, 2013, 2, 91.	0.2	115
7	Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell, 2018, 34, 792-806.e5.	7.7	102
8	Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity. PLoS ONE, 2013, 8, e76164.	1.1	94
9	A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. Cancer, 2019, 125, 3184-3197.	2.0	73
10	Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer. Frontiers in Oncology, 2019, 9, 86.	1.3	71
11	A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncology, 2015, 51, 279-286.	0.8	65
12	Lung cancer in the Indian subcontinent. South Asian Journal of Cancer, 2016, 05, 095-103.	0.2	63
13	EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy. PLoS ONE, 2013, 8, e61561.	1.1	61
14	Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. The Lancet Global Health, 2020, 8, e1213-e1222.	2.9	57
15	Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer. Journal of Clinical Oncology, 2019, 37, 3032-3041.	0.8	51
16	A fresh look at oncology facts on south central Asia and SAARC countries. South Asian Journal of Cancer, 2012, 01, 01-04.	0.2	49
17	Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open, 2017, 2, e000168.	2.0	48
18	Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study. Journal of Thoracic Oncology, 2014, 9, 991-997.	0.5	46

#	Article	IF	CITATIONS
19	EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?. OncoTargets and Therapy, 2017, Volume 10, 1859-1863.	1.0	44
20	Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. Lung Cancer, 2016, 93, 95-103.	0.9	41
21	Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: long-term and mature outcomes of a prospective randomized trial. Radiation Oncology, 2020, 15, 218.	1.2	38
22	Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non–Small-Cell Lung Cancer. Journal of Global Oncology, 2017, 3, 208-217.	0.5	33
23	Human papillomavirus in head and neck cancer in India: Current status and consensus recommendations. South Asian Journal of Cancer, 2017, 06, 093-098.	0.2	33
24	Indian clinical practice consensus guidelines for the management of squamous cell carcinoma of head and neck. Indian Journal of Cancer, 2020, 57, 1.	0.2	32
25	Low prevalence of transcriptionally active human papilloma virus in Indian patients with HNSCC and leukoplakia. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016, 122, 609-618.e7.	0.2	31
26	Clinical Outcomes With Dose-Escalated Adaptive Radiation Therapy for Urinary Bladder Cancer: A Prospective Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 60-66.	0.4	30
27	Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment. OncoTargets and Therapy, 2017, Volume 10, 2903-2908.	1.0	29
28	Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis. Oral Oncology, 2018, 76, 52-60.	0.8	29
29	<p>Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis</p> . Lung Cancer: Targets and Therapy, 2019, Volume 10, 1-10.	1.3	29
30	COVIDâ€19 in cancer patients on active systemic therapy – Outcomes from LMIC scenario with an emphasis on need for active treatment. Cancer Medicine, 2020, 9, 8747-8753.	1.3	29
31	ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country. PLoS ONE, 2016, 11, e0160752.	1.1	28
32	Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study. Journal of Thoracic Oncology, 2021, 16, 1733-1744.	0.5	26
33	Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study. OncoTargets and Therapy, 2014, 7, 1051.	1.0	25
34	Salvage surgery in head and neck cancer: Does it improve outcomes?. European Journal of Surgical Oncology, 2020, 46, 1052-1058.	0.5	25
35	The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients. Chemotherapy Research and Practice, 2014, 2014, 1-4.	1.6	24
36	A systematic approach to diagnosis of cystic brain lesions. South Asian Journal of Cancer, 2013, 2, 98.	0.2	24

#	Article	IF	CITATIONS
37	Outcomes of surgically treated oral cancer patients at a tertiary cancer center in India. Indian Journal of Cancer, 2017, 54, 616.	0.2	24
38	Induction Chemotherapy in Technically Unresectable Locally Advanced Carcinoma of Maxillary Sinus. Chemotherapy Research and Practice, 2014, 2014, 1-6.	1.6	23
39	Clinical impact of prostate specific antigen (PSA) inter-assay variability on management of prostate cancer. Clinical Biochemistry, 2016, 49, 79-84.	0.8	22
40	Initial experience of a geriatric oncology clinic in a tertiary cancer center in India. Cancer Research Statistics and Treatment, 2020, 3, 208.	0.1	22
41	Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer. Journal of Clinical Oncology, 2022, 40, 272-281.	0.8	22
42	Analysis of solid tumor mutation profiles in liquid biopsy. Cancer Medicine, 2018, 7, 5439-5447.	1.3	21
43	Depth of invasion, size and number of metastatic nodes predicts extracapsular spread in early oral cancers with occult metastases. Oral Oncology, 2018, 81, 95-99.	0.8	20
44	Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer Journal of Clinical Oncology, 2017, 35, 6007-6007.	0.8	20
45	Chronic myeloid leukemia data from India. Indian Journal of Medical and Paediatric Oncology, 2013, 34, 154-158.	0.1	20
46	Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 161-165.	0.1	20
47	Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation). International Journal of Surgical Oncology, 2016, 2016, 1-8.	0.3	18
48	Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects. Expert Review of Anticancer Therapy, 2020, 20, 17-29.	1.1	17
49	Beyond conventional chemotherapy, targeted therapy and immunotherapy in squamous cell cancer of the oral cavity. Oral Oncology, 2020, 105, 104673.	0.8	17
50	A realâ€world data of Immune checkpoint inhibitors in solid tumors from India. Cancer Medicine, 2021, 10, 1525-1534.	1.3	17
51	Expectations and preferences for palliative chemotherapy in head and neck cancers patients. Oral Oncology, 2016, 63, 10-15.	0.8	16
52	Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing. Advances in Therapy, 2019, 36, 766-785.	1.3	16
53	Phase III randomized trial of surgery followed by conventional radiotherapy (5 fr/Wk) (Arm A) vs concurrent chemoradiotherapy (Arm B) vs accelerated radiotherapy (6fr/Wk) (Arm C) in locally advanced, stage III and IV, resectable, squamous cell carcinoma of oral cavity- oral cavity adjuvant therapy (OCAT): Final results (NCT00193843) Journal of Clinical Oncology, 2016, 34, 6004-6004.	0.8	16
54	Metronomic chemotherapy in advanced oral cancers. Journal of Cancer Research and Therapeutics, 2012, 8, 106.	0.3	16

#	Article	IF	CITATIONS
55	Aprepitant for Cough Suppression in Advanced Lung Cancer. Chest, 2020, 157, 1647-1655.	0.4	15
56	Neoadjuvant chemotherapy in advanced sinonasal teratocarcinosarcoma with intracranial extension: Report of two cases with literature review. Journal of Cancer Research and Therapeutics, 2015, 11, 1003.	0.3	15
57	Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India. Supportive Care in Cancer, 2016, 24, 1595-1602.	1.0	14
58	68 Ga labeled Erlotinib: A novel PET probe for imaging EGFR over-expressing tumors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4552-4557.	1.0	14
59	Optimum surgical margins in squamous cell carcinoma of the oral tongue: Is the current definition adequate?. Oral Oncology, 2020, 111, 104938.	0.8	14
60	Effect of Early Palliative Care on Quality of Life of Advanced Head and Neck Cancer Patients: A Phase III Trial. Journal of the National Cancer Institute, 2021, 113, 1228-1237.	3.0	14
61	<i>Fusobacterium nucleatum</i> is associated with inflammation and poor survival in early-stage HPV-negative tongue cancer. NAR Cancer, 2022, 4, zcac006.	1.6	14
62	Gender climate in Indian oncology: national survey report. ESMO Open, 2020, 5, e000671.	2.0	13
63	Systemic therapy for limited stage small cell lung carcinoma. Journal of Thoracic Disease, 2020, 12, 6275-6290.	0.6	13
64	Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations. Oncotarget, 2021, 12, 578-588.	0.8	13
65	Prognostic value of a patient-reported functional score versus physicianreported Karnofsky Performance Status Score in brain metastases. Ecancermedicalscience, 2017, 11, 779.	0.6	12
66	Prognostic and predictive significance of nuclear HIF1α expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab. British Journal of Cancer, 2020, 123, 1757-1766.	2.9	12
67	Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer. Oncotarget, 2020, 11, 399-408.	0.8	12
68	Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?. South Asian Journal of Cancer, 2016, 05, 182-185.	0.2	12
69	Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer. Oral Oncology, 2017, 75, 54-60.	0.8	11
70	Impact of age on elderly patients with oral cancer. European Archives of Oto-Rhino-Laryngology, 2019, 276, 223-231.	0.8	11
71	Positron emission tomography in mucosal melanomas of head and neck: Results from a South Asian tertiary cancer care center. World Journal of Nuclear Medicine, 2017, 16, 197-201.	0.3	11
72	A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers. South Asian Journal of Cancer, 2017, 06, 011-014.	0.2	11

#	Article	IF	CITATIONS
73	Kidney cancer demographics and outcome data from 2013 at a tertiary cancer hospital in India. Indian Journal of Cancer, 2017, 54, 601.	0.2	11
74	Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6–8 May 2016, Mumbai. Ecancermedicalscience, 2016, 10, 689.	0.6	10
75	Adherence to and Implementation of ASCO Antiemetic Guidelines in Routine Practice in a Tertiary Cancer Center in India. Journal of Oncology Practice, 2017, 13, e574-e581.	2.5	10
76	Outcomes of a Telephone-Based Questionnaire for Follow-up of Patients Who Have Completed Curative-Intent Treatment for Oral Cancers. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 1102.	1.2	10
77	Neuroendocrine Neoplasms of the Larynx: A Clinicopathologic Analysis of 27 Neuroendocrine Tumors and Neuroendocrine Carcinomas. Head and Neck Pathology, 2022, 16, 375-387.	1.3	10
78	Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone – Additional data from a phase 3 trial. Oral Oncology, 2021, 122, 105517.	0.8	10
79	Bladder cancer demographics and outcome data from 2013 at a tertiary cancer hospital in India. Indian Journal of Cancer, 2019, 56, 54.	0.2	10
80	Prognostic Impact of Pattern of Mandibular Involvement in Gingivo-Buccal Complex Squamous Cell Carcinomas: Marrow and Mandibular Canal Staging System. Frontiers in Oncology, 2021, 11, 752018.	1.3	10
81	Prognostic Value of Radiological Extranodal Extension Detected by Computed Tomography for Predicting Outcomes in Patients With Locally Advanced Head and Neck Squamous Cell Cancer Treated With Radical Concurrent Chemoradiotherapy. Frontiers in Oncology, 2022, 12, .	1.3	10
82	Checkpoint inhibitor accessibility in 15,000+ Indian patients Journal of Clinical Oncology, 2022, 40, 9012-9012.	0.8	10
83	Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer. JCO Global Oncology, 2022, , .	0.8	10
84	Patterns of failure and outcomes in cT4 Oral squamous cell carcinoma (OSCC) undergoing upfront surgery in comparison to Neo-Adjuvant Chemotherapy (NACT) followed by surgery: A Matched Pair analysis. Oral Oncology, 2020, 100, 104455.	0.8	9
85	Should we wait or not? The preferable option for patients with stage IV oral cancer in COVID â€19 pandemic. Head and Neck, 2020, 42, 1173-1178.	0.9	9
86	Adamantinoma-Like Ewing Sarcoma of the Head and Neck: A Case-Series of a Rare and Challenging Diagnosis. Head and Neck Pathology, 2022, 16, 679-694.	1.3	9
87	Carcinomatous meningitis in non-small cell lung cancer: Palliation with intrathecal treatment. Indian Journal of Medical and Paediatric Oncology, 2014, 35, 75-78.	0.1	8
88	Locoregional recurrence after cystectomy in muscle invasive bladder cancer: Implications for adjuvant radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 496.e9-496.e15.	0.8	8
89	Sunitinib-induced thrombotic microangiopathy. Journal of Cancer Research and Therapeutics, 2016, 12, 6.	0.3	8
90	Head and neck squamous cell carcinoma in HIV, HBV and HCV seropositive patients - Prognosis and its predictors. Journal of Cancer Research and Therapeutics, 2020, 16, 619-623.	0.3	8

#	Article	IF	CITATIONS
91	Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update. South Asian Journal of Cancer, 2019, 08, 01-17.	0.2	8
92	Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients. South Asian Journal of Cancer, 2018, 07, 249-252.	0.2	8
93	Clozapine and cancer treatment: Adding to the experience and evidence. Indian Journal of Psychiatry, 2014, 56, 191.	0.4	7
94	Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas - Experience From a Tertiary Cancer Centre in India. Frontiers in Oncology, 2021, 11, 710585.	1.3	7
95	Indian clinical practice consensus guidelines for the management of oropharyngeal cancer. Indian Journal of Cancer, 2020, 57, 12.	0.2	7
96	Prognostic significance of pretreatment sodium levels in patients of nonsmall cell lung cancer treated with pemetrexed-platinum doublet chemotherapy. Journal of Cancer Research and Therapeutics, 2018, 14, 1049.	0.3	7
97	Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer. South Asian Journal of Cancer, 2016, 05, 067-069.	0.2	7
98	Role of neoadjuvant chemotherapy in advanced carcinoma of the hypopharynx and larynx. South Asian Journal of Cancer, 2017, 06, 015-019.	0.2	7
99	Thyroid cancer in Gardner's syndrome: Case report and review of literature. South Asian Journal of Cancer, 2012, 01, 43-47.	0.2	7
100	A study to assess the feasibility of introducing early palliative care in ambulatory patients with advanced lung cancer. Indian Journal of Palliative Care, 2017, 23, 261.	1.0	7
101	Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey. South Asian Journal of Cancer, 2018, 07, 203-206.	0.2	7
102	Excellent response to erlotinib in breast carcinoma with rare EGFR mutation—a case report. Ecancermedicalscience, 2020, 14, 1092.	0.6	7
103	G8 and VES-13 as screening tools for geriatric assessment and predictors of survival in older Indian patients with cancer. Journal of Geriatric Oncology, 2022, 13, 720-730.	0.5	7
104	High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy. Cancer Management and Research, 2014, 6, 261.	0.9	6
105	Neoadjuvant chemotherapy and surgical margin in technically unresectable buccal mucosa cancers. Oral Oncology, 2015, 51, e91-e92.	0.8	6
106	Efficacy and Safety of Induction Chemotherapy in Esophageal Cancer with Airway Involvement. Journal of Gastrointestinal Cancer, 2016, 47, 294-304.	0.6	6
107	Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma—Results From a Tertiary Cancer Center in India. Clinical Genitourinary Cancer, 2017, 15, e345-e355.	0.9	6
108	Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer. EClinicalMedicine, 2019, 9, 19-25.	3.2	6

#	Article	IF	CITATIONS
109	Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1–5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial. BMJ Open, 2021, 11, e043628.	0.8	6
110	Distress Screening in Head and Neck Cancer Patients Planned for Cancerâ€Directed Radiotherapy. Laryngoscope, 2021, 131, 2023-2029.	1.1	6
111	Outcomes of osteosarcoma, chondrosarcoma and chordoma treated with image guided-intensity modulated radiation therapy. Radiotherapy and Oncology, 2021, 164, 216-222.	0.3	6
112	Exploratory analysis of safety by histology and efficacy in a nonsquamous NSCLC subgroup in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) vs DOC for second-line treatment of stage IV non-small-cell lung cancer (NSCLC) Journal of Clinical Oncology, 2015, 33, 8055-8055.	0.8	6
113	Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases. Indian Journal of Cancer, 2017, 54, 678.	0.2	6
114	An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome. South Asian Journal of Cancer, 2020, 09, 06-12.	0.2	6
115	Phase III randomized trial comparing intravenous to oral iron in patients with cancerâ€related iron deficiency anemia not on erythropoiesis stimulating agents. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e129-e137.	0.7	6
116	Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?. Urology Annals, 2014, 6, 18.	0.3	5
117	Potential role of metronomic chemotherapy in the treatment of esophageal and gastroesophageal cancer. Cancer Letters, 2017, 400, 267-275.	3.2	5
118	Neoadjuvant chemotherapy in geriatric head and neck cancers. Head and Neck, 2017, 39, 886-892.	0.9	5
119	Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study. Ecancermedicalscience, 2018, 12, 876.	0.6	5
120	Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases. European Journal of Clinical Pharmacology, 2020, 76, 1427-1436.	0.8	5
121	Concurrent chemoradiotherapy for locally advanced unresectable adenoid cystic carcinoma of head and neck: experience from a single institute. European Archives of Oto-Rhino-Laryngology, 2021, 278, 4423-4431.	0.8	5
122	Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer. Expert Review of Precision Medicine and Drug Development, 2021, 6, 161-171.	0.4	5
123	Advances in pharmacotherapy for head and neck cancer. Expert Opinion on Pharmacotherapy, 2021, 22, 2007-2018.	0.9	5
124	Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings. Ecancermedicalscience, 2020, 14, 1038.	0.6	5
125	Indian clinical practice consensus guidelines for the management of oral cavity cancer. Indian Journal of Cancer, 2020, 57, 6.	0.2	5
126	Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 238-242.	0.1	5

#	Article	IF	CITATIONS
127	Metronomic palliative chemotherapy in maxillary sinus tumor. South Asian Journal of Cancer, 2016, 05, 056-058.	0.2	5
128	Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis. South Asian Journal of Cancer, 2018, 07, 226-230.	0.2	5
129	The clinical utility and safety of shortâ€course immune checkpoint inhibitors in multiple tumours—A realâ€world multicentric study from India. International Journal of Cancer, 2021, , .	2.3	5
130	Prognostic and predictive roles of cancer stem cell markers in head and neck squamous cell carcinoma patients receiving chemoradiotherapy with or without nimotuzumab. British Journal of Cancer, 2022, 126, 1439-1449.	2.9	5
131	Definitive and adjuvant radiation therapy for external auditory canal and temporal bone squamous cell carcinomas: Long term outcomes. Radiotherapy and Oncology, 2022, 170, 151-158.	0.3	5
132	Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 751-759.	1.1	5
133	The rationality of combining second-generation antiandrogens with 177Lu-PSMA or its alpha-emitting congeners for better and durable results. Nuclear Medicine Communications, 2018, 39, 1061-1063.	0.5	4
134	Tackling brain metastases from lung cancer during the <scp>COVID</scp> â€19 pandemic. Cancer Reports, 2022, 5, e1276.	0.6	4
135	Intensityâ€modulated radiation therapy for nasal cavity and paranasal sinus tumors: Experience from a single institute. Head and Neck, 2021, 43, 2045-2057.	0.9	4
136	Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study. Cancer Medicine, 2021, 10, 6725-6735.	1.3	4
137	Inhibition of Interleukin-6 (IL-6) Reverses Anemia In Patients with Advanced Non Small Cell Lung Cancer (NSCLC): Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Blood, 2010, 116, 640-640.	0.6	4
138	A phase II randomized control trial of erlotinib in combination with celecoxib in patients with operable oral squamous cell carcinoma (OSCC): Erlo-Xib Study Journal of Clinical Oncology, 2019, 37, 6054-6054.	0.8	4
139	Indian clinical practice consensus guidelines for the management of very advanced disease of squamous cell carcinoma of head and neck. Indian Journal of Cancer, 2020, 57, 22.	0.2	4
140	EMERALD: Emergency visit audit of patients treated under medical oncology in a tertiary cancer center: Logical steps to decrease the burden. South Asian Journal of Cancer, 2017, 06, 186-189.	0.2	4
141	Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer. South Asian Journal of Cancer, 2017, 06, 143-146.	0.2	4
142	Indian clinical practice consensus guidelines for the management of nasopharyngeal cancer. Indian Journal of Cancer, 2020, 57, 9.	0.2	4
143	Indian clinical practice consensus guidelines for the management of hypopharyngeal cancer. Indian Journal of Cancer, 2020, 57, 16.	0.2	4
144	Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC). Ecancermedicalscience, 2021, 15, 1325.	0.6	4

#	Article	IF	CITATIONS
145	Lymphopenia during chemoradiationâ \in "foe or friend. Ecancermedicalscience, 2020, 14, 1109.	0.6	4
146	Incidence and impact of Dihydropyrimidine dehydrogenase gene mutation on neoadjuvant chemotherapy in head and neck cancers. Oral Oncology, 2017, 70, 73-74.	0.8	3
147	Feasibility of molecular testing in a multicenter study with geographical variation in India: Epidermal growth factor receptor mutation as a model molecular test. Asian Journal of Oncology, 2017, 03, 039-044.	0.2	3
148	Survey of Implementation of Antiemetic Prescription Standards in Indian Oncology Practices and Its Adherence to the American Society of Clinical Oncology Antiemetic Clinical Guideline. Journal of Global Oncology, 2017, 3, 346-359.	0.5	3
149	Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer. BMJ Open, 2021, 11, e041345.	0.8	3
150	Adolescent–adult nonmetastatic Ewing sarcoma—Experience from a large developing country. Pediatric Blood and Cancer, 2021, 68, e29081.	0.8	3
151	The epidemiological trend of esophageal cancer in Mumbai, India over the past two decades Journal of Clinical Oncology, 2021, 39, e16095-e16095.	0.8	3
152	ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients. Cancer Medicine, 2021, 10, 4948-4956.	1.3	3
153	Weight loss and its impact on outcome in head and cancer patients during chemo-radiation. Oral Oncology, 2021, 122, 105522.	0.8	3
154	Deep learning-based predictive imaging biomarker model for EGFR mutation status in non-small cell lung cancer from CT imaging Journal of Clinical Oncology, 2020, 38, 3106-3106.	0.8	3
155	Correlation of CTCs with disease progression in Indian oral cancer patients Journal of Clinical Oncology, 2020, 38, e15541-e15541.	0.8	3
156	Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?. Lung India, 2018, 35, 27.	0.3	3
157	Neoadjuvant chemotherapy in technically unresectable carcinoma of external auditory canal. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 172-175.	0.1	3
158	Oncology gold standard® practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck. South Asian Journal of Cancer, 2017, 06, 154-160.	0.2	3
159	Aprepitant in weekly cisplatin with radiation in head and neck cancer: Is it required?. Journal of Clinical Oncology, 2020, 38, e24122-e24122.	0.8	3
160	Indian clinical practice consensus guidelines for the management of laryngeal cancer. Indian Journal of Cancer, 2020, 57, 19.	0.2	3
161	Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation. Translational Oncology, 2022, 22, 101461.	1.7	3
162	A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non–Small Cell Lung Cancer. Clinical Pharmacology in Drug Development, 2017, 6, 234-239.	0.8	2

#	Article	IF	CITATIONS
163	Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy. Ecancermedicalscience, 2017, 11, 776.	0.6	2
164	Metastatic Renal Cell Cancer—Systemic Therapy. Indian Journal of Surgical Oncology, 2018, 9, 97-104.	0.3	2
165	Utility of response assessment PET-CT to predict residual disease in neck nodes: A comparison with the Histopathology. Auris Nasus Larynx, 2019, 46, 599-604.	0.5	2
166	Clinical outcomes for nasopharyngeal cancer with intracranial extension after taxaneâ€based induction chemotherapy and concurrent chemoâ€radiotherapy in the modern era. World Journal of Otorhinolaryngology - Head and Neck Surgery, 2020, 6, 25-33.	0.7	2
167	Accuracy of the CARG chemotherapy toxicity risk prediction tool in older Indian patients with cancer Journal of Clinical Oncology, 2021, 39, e24023-e24023.	0.8	2
168	Oral and dental health status in patients undergoing neoadjuvant chemotherapy for locally advanced head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2021, 132, 539-548.	0.2	2
169	Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs. Translational Oncology, 2021, 14, 101111.	1.7	2
170	Primary mediastinal germ cell tumours with high prevalence of somatic malignancy: An experience from a single tertiary care oncology centre. Annals of Diagnostic Pathology, 2021, 53, 151763.	0.6	2
171	Metastasis to Appendix Presenting as Acute Appendicitis—A Rare Case Report and Review of Literature. Journal of Gastrointestinal Cancer, 2021, 52, 1114-1118.	0.6	2
172	Practice Patterns and Outcomes for Pemetrexed Plus Platinum Doublet as Neoadjuvant Chemotherapy in Adenocarcinomas of Lung: Looking Beyond the Usual Paradigm. Clinical Oncology, 2018, 30, 23-29.	0.6	2
173	NACT in locally advanced oral cancers : Does HPV make a difference?. Journal of Clinical Oncology, 2015, 33, e17068-e17068.	0.8	2
174	Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer Journal of Clinical Oncology, 2017, 35, 6018-6018.	0.8	2
175	Low-cost oral metronomic versus intravenous chemotherapy in recurrent, inoperable and metastatic head and neck cancer: Phase III Metro-CIS study Journal of Clinical Oncology, 2020, 38, 6506-6506.	0.8	2
176	Comparison of postoperative complications in advanced head and neck cancer patients receiving neoadjuvant chemotherapy followed by surgery versus surgery alone. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 249-254.	0.1	2
177	Are three drugs better than two and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?. Journal of Clinical Oncology, 2013, 31, 6085-6085.	0.8	2
178	CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons. F1000Research, 2015, 4, 160.	0.8	2
179	Reference Data for Standardized Quality of Life Questionnaires in Indian Patients with Brain Metastases from Non-small Cell Lung Cancer: Results from a Prospective Study. Cureus, 2017, 9, e1149.	0.2	2
180	Incidence of 5-fluorouracil related in cardiotoxicity in patients with head and neck cancer Journal of Clinical Oncology, 2020, 38, e24123-e24123.	0.8	2

#	Article	IF	CITATIONS
181	Chemoradiation in Unresectable Oral Cavity Cancer: A Myth or Reality!. South Asian Journal of Cancer, 2020, 09, 195-198.	0.2	2
182	Pembrolizumab weight based dosing – A call for policy change. Indian Journal of Medical and Paediatric Oncology, 2022, 43, 306-310.	0.1	2
183	Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with <scp>onceâ€aâ€week</scp> versus <scp>onceâ€everyâ€3â€weeks</scp> cisplatin. Cancer Medicine, 2022, 11, 3939-3948.	1.3	2
184	Safety and efficacy of pembrolizumab with chemotherapy in locally advanced head and neck cancers. Oral Oncology, 2022, 127, 105824.	0.8	2
185	RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation. Oral Oncology, 2022, 128, 105816.	0.8	2
186	CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer. Indian Journal of Cancer, 2022, 59, 11.	0.2	2
187	Translation and Validation of COST - FACIT (Version 2) Questionnaire into Hindi and Marathi to Assess Financial Toxicity in Indian Cancer Patients. South Asian Journal of Cancer, 2022, 11, 097-104.	0.2	2
188	Bilateral visual blurring as the first symptom of extra-cranial metastatic lung carcinoma. Indian Journal of Medical and Paediatric Oncology, 2012, 33, 48.	0.1	1
189	Technically unresectable recurrent oral cancers: Is NACT the answer?. Oral Oncology, 2016, 56, e12-e14.	0.8	1
190	P3.02b-055 Impact of Pemetrexed Chemotherapy in Exon 19 or Exon 21 Mutated NSCLC. Journal of Thoracic Oncology, 2017, 12, S1223.	0.5	1
191	Bayesian relative survival : An illustration with lung cancer patients data. Journal of Statistics and Management Systems, 2017, 20, 325-336.	0.3	1
192	Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?. Chemotherapy Research and Practice, 2017, 2017, 1-4.	1.6	1
193	The role of chemotherapy in patients with small cell lung cancer and poor performance status. Acta Oncológica, 2020, 59, 1520-1527.	0.8	1
194	Correlation of transcriptionally active human papillomavirus status with the clinical and molecular profiles of head and neck squamous cell carcinomas. Head and Neck, 2021, 43, 2032-2044.	0.9	1
195	Post hoc analysis of a randomized controlled trial comparing concurrent chemoradiation with cisplatin versus nimotuzumab-cisplatin, focusing on acute oral mucositis. Journal of the Egyptian National Cancer Institute, 2021, 33, 12.	0.6	1
196	Systemic Therapy in Thyroid Cancer. Indian Journal of Surgical Oncology, 2022, 13, 68-80.	0.3	1
197	An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settings. Ecancermedicalscience, 2021, 15, 1274.	0.6	1
198	782 PATTERNS OF FAILURE AND ADEQUACY OF CLINICAL TARGET VOLUME (CTV) MARGINS IN PATIENTS TREATED WITH DEFINITIVE CHEMO-RADIATION IN ESOPHAGEAL CANCER. Ecological Management and Restoration, 2021, 34, .	0.2	1

#	Article	IF	CITATIONS
199	Validation of a novel causality assessment scale for adverse events in non-small cell lung carcinoma patients treated with platinum and pemetrexed doublet chemotherapy. Therapeutic Advances in Drug Safety, 2021, 12, 204209862199128.	1.0	1
200	A highly efficient, low-cost, novel multicomponent nanosystem for rapid enumeration of circulating tumor cells Journal of Clinical Oncology, 2019, 37, e14516-e14516.	0.8	1
201	Effect of early integration of specialized palliative care into standard oncologic treatment on the quality of life of patients with advanced head and neck cancers: A phase III randomized controlled trial Journal of Clinical Oncology, 2020, 38, 12013-12013.	0.8	1
202	An Algorithm to Define the Optimum Biological Dose of Metronomic Chemotherapy. Biometrical Letters, 2018, 55, 1-15.	0.4	1
203	Aggressive surgery in palliative setting of lung cancer: Is it helpful?. Indian Journal of Palliative Care, 2016, 22, 504.	1.0	1
204	Geriatric oncology: The need of the hour. South Asian Journal of Cancer, 2013, 02, 200-201.	0.2	1
205	An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma. South Asian Journal of Cancer, 2019, 08, 159-165.	0.2	1
206	Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer. South Asian Journal of Cancer, 2018, 07, 194-202.	0.2	1
207	Predicting complications of chemotherapy-induced febrile neutropenia: A single-center experience Journal of Clinical Oncology, 2013, 31, e20678-e20678.	0.8	1
208	Epidemiology of oral cancers referred for NACT, the demographics, clinical profile, and organ functions Journal of Clinical Oncology, 2013, 31, e12520-e12520.	0.8	1
209	A phase II study comparing metronomic chemotherapy with chemotherapy (single-agent cisplatin), in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of head and neck Journal of Clinical Oncology, 2014, 32, 6017-6017.	0.8	1
210	Agreement analysis between three different short geriatric screening scales in patients undergoing chemotherapy for solid tumors. Journal of Cancer Research and Therapeutics, 2016, 13, 1023-1026.	0.3	1
211	Feasibility and outcome of repeat biopsy upon progression on tyrosine kinase inhibitors in patients with EGFR mutation positive adenocarcinoma of lung-an Indian tertiary cancer centre experience Journal of Clinical Oncology, 2017, 35, e20628-e20628.	0.8	1
212	Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience Journal of Clinical Oncology, 2018, 36, e15065-e15065.	0.8	1
213	Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid. South Asian Journal of Cancer, 2019, 08, 185-188.	0.2	1
214	Palliative chemotherapy in carcinoma nasopharynx. South Asian Journal of Cancer, 2019, 08, 173-177.	0.2	1
215	Use of Iorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience. South Asian Journal of Cancer, 2019, 08, 211-225.	0.2	1
216	Prognostic value of radiological extranodal extension detected by computed tomography for predicting outcomes in head and neck squamous cell cancer patients treated with radical chemoradiotherapy Journal of Clinical Oncology, 2020, 38, 6560-6560.	0.8	1

#	Article	IF	CITATIONS
217	Contemporary management and associated outcomes of 3,151 patients with stage III non-small cell lung cancer (NSCLC) in a real-world setting: Results of KINDLE, a multicountry observational study Journal of Clinical Oncology, 2020, 38, 9043-9043.	0.8	1
218	A prospective analysis of chemotherapy-induced nausea and vomiting in gastrointestinal cancers: Results from a tertiary cancer center Journal of Clinical Oncology, 2020, 38, 12111-12111.	0.8	1
219	CONCORDANCE study: An observational, multicenter, prospective study to evaluate concordance of detecting EGFR mutations by circulating tumor-free DNA versus tissues biopsy in NSCLC Journal of Clinical Oncology, 2020, 38, e21615-e21615.	0.8	1
220	Optimal cumulative cisplatin dose for radio-sensitization in locally advanced head and neck cancer Journal of Clinical Oncology, 2020, 38, e18553-e18553.	0.8	1
221	Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer. Oncotarget, 2019, 10, 6297-6307.	0.8	1
222	A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer. South Asian Journal of Cancer, 2020, 09, 23-26.	0.2	1
223	Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non–Small Cell Lung Cancer. JAMA Oncology, 2021, , .	3.4	1
224	Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience. South Asian Journal of Cancer, 2020, 09, 180-182.	0.2	1
225	Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation $\hat{a} \in $ a phase 3 study. Ecancermedicalscience, 2021, 15, 1318.	0.6	1
226	Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review. South Asian Journal of Cancer, 0, , .	0.2	1
227	Change in Pattern of Failure in Head and Neck Cancer. Journal of Clinical Oncology, 0, , .	0.8	1
228	Real-world data of use of nivolumab in platinum refractory head and neck cancers Journal of Clinical Oncology, 2022, 40, e18686-e18686.	0.8	1
229	Oral cutaneous leishmaniasis mimicking carcinoma of tongue: A case report. Indian Journal of Cancer, 2014, 51, 401.	0.2	0
230	Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre. Case Reports in Oncology, 2016, 9, 506-515.	0.3	0
231	Curative intent therapy in oligometastatic lung cancer with an unresectable primary with N3 nodes: case report and review of the literature. Lung Cancer Management, 2016, 5, 21-27.	1.5	0
232	Extra-lymphatic filariasis at reconstructive surgery flap site recurrence of head and neck cancer. IDCases, 2016, 3, 8-9.	0.4	0
233	Evolving Management Strategies and Controversies in Early-Stage Lung Cancer. Journal of Oncology Practice, 2017, 13, 79-81.	2.5	0
234	Incremental value of endoscopic brush cytology in response assessment after chemo-irradiation for Esophageal cancer. Journal of Gastrointestinal Cancer, 2020, , 1.	0.6	0

#	Article	IF	CITATIONS
235	Reply to T. Tanaka et al and F. Liang. Journal of Clinical Oncology, 2020, 38, 844-846.	0.8	0
236	Oral metronomic therapy in head and neck cancer – Authors' reply. The Lancet Global Health, 2021, 9, e21.	2.9	0
237	Study of Treatment Outcome in Adults with TFE-Related RCC. South Asian Journal of Cancer, 2021, 10, 92-96.	0.2	Ο
238	Caregiver burden in older Indian patients with cancer: Experience from a tertiary care center Journal of Clinical Oncology, 2021, 39, e24022-e24022.	0.8	0
239	The use of G8 and VES13 as screening and prognostic tools in older Indian patients with cancer Journal of Clinical Oncology, 2021, 39, e24024-e24024.	0.8	0
240	Weekly osimertinib dosing to prevent <i>EGFR</i> mutant tumor cells destined to home mouse lungs Journal of Clinical Oncology, 2021, 39, e20504-e20504.	0.8	0
241	Bayesian Effective Biological Dose Determination in Immunotherapy Response Trial. Annals of Data Science, 0, , 1.	1.7	0
242	An Audit of Systemic Therapy in Medullary Carcinoma Thyroid. Indian Journal of Surgical Oncology, 2022, 13, 61-67.	0.3	0
243	287 OUTCOMES OF DEFINITIVE CHEMORADIOTHERAPY IN LONG SEGMENT ESOPHAGEAL CANCERS FROM A TERTIARY CANCER CENTRE IN INDIA. Ecological Management and Restoration, 2021, 34, .	0.2	Ο
244	Retrospective analysis of intravenous iron-sucrose therapy in patients undergoing chemotherapy at a tertiary-care center in India Journal of Clinical Oncology, 2012, 30, e13068-e13068.	0.8	0
245	Distant metastasis in head and neck cancer: Baseline factors Journal of Clinical Oncology, 2012, 30, e16021-e16021.	0.8	Ο
246	An evaluation of phase I clinical trial designs of chemotherapeutic agents tested on solid tumors and approved in last 10 years Journal of Clinical Oncology, 2012, 30, e13127-e13127.	0.8	0
247	The changing landscape of hormonal therapy in castration-resistant prostate cancer. South Asian Journal of Cancer, 2012, 01, 53-55.	0.2	0
248	The cure for a racing heart. South Asian Journal of Cancer, 2013, 2, 169.	0.2	0
249	Neoadjuvant DCF in resectable esophageal cancer: Single-center experience Journal of Clinical Oncology, 2013, 31, 124-124.	0.8	0
250	Quality of life and safety profile of pemetrexed-platinum doublet in Indian adult chemo-naive NSCLC patients Journal of Clinical Oncology, 2013, 31, e19118-e19118.	0.8	0
251	Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer: A phase II, open-label, multicenter, randomized study Journal of Clinical Oncology, 2013, 31, 8053-8053.	0.8	0
252	Acute toxicity of neoadjuvant chemotherapy in oral cavity cancers: Can it be predicted?. Journal of Clinical Oncology, 2013, 31, e17027-e17027.	0.8	0

#	Article	IF	CITATIONS
253	Final efficacy and safety results of pemetrexed (pem) continuation maintenance (mtc) therapy in the elderly from the PARAMOUNT phase III study Journal of Clinical Oncology, 2013, 31, 8068-8068.	0.8	0
254	Confusion worse confounded. South Asian Journal of Cancer, 2013, 02, 278-278.	0.2	0
255	Audio visual recording of informed consent: Novel mandatory regulatory compliance for clinical trials in India Journal of Clinical Oncology, 2014, 32, e17672-e17672.	0.8	0
256	Neoadjuvant chemotherapy in very locally advanced technically unresectable oral cavity cancers Journal of Clinical Oncology, 2014, 32, e17033-e17033.	0.8	0
257	Renal impairment in prostate cancer: A close look is important. Indian Journal of Cancer, 2015, 52, 113.	0.2	0
258	Excellent response to oral Metronomic chemotherapy in unresectable adenocarcinoma of external auditory canal. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 132-132.	0.1	0
259	Compliance to NACT in T4 oral cancers :The place, person, socioeconomic status or assistance Journal of Clinical Oncology, 2015, 33, e17534-e17534.	0.8	0
260	A cross sectional retrospective study regarding patients and their physician willingness to wait for driver mutation report in NSCLC Journal of Clinical Oncology, 2015, 33, e17532-e17532.	0.8	0
261	Epidemiology of male seminomatous (SGCT) and non-seminomatous germ cell tumours (NSGCT) and response to first line chemotherapy (CT) from a tertiary cancer centre in India Journal of Clinical Oncology, 2015, 33, e15553-e15553.	0.8	0
262	Prognostic importance of pretreatment sodium levels in patients of NSCLC treated with pemetrexed-platinum doublet chemotherapy Journal of Clinical Oncology, 2015, 33, e18510-e18510.	0.8	0
263	A cross-sectional observation study regarding patients and their physician willingness to wait for driver mutation report in nonsmall-cell lung cancer. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 74-78.	0.1	0
264	Survey of implementation of antiemetic prescription standards in Indian oncology practices and adherence to ASCO's antiemetic clinical guideline Journal of Clinical Oncology, 2016, 34, e18230-e18230.	0.8	0
265	Toxicity, tolerance and outcomes of carboplatin based CTRT (concurrent chemoradiation) in head and neck cancers in patients who were not fit for cisplatin based CTRT Journal of Clinical Oncology, 2016, 34, e17539-e17539.	0.8	0
266	Poor risk advanced renal cell carcinoma: Outcomes from a registry in a tertiary cancer center. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 311.	0.1	0
267	Outcomes with Palliative Weekly Paclitaxel in Advanced, Recurrent, and Metastatic Esophageal Cancer -ÂReal World Experience. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 46-51.	0.1	0
268	Tyrosine kinase inhibitor versus physician choice chemotherapy in second-line epidermal growth factor receptor mutation non-small cell lung cancer: Post hoc analysis of randomized control trial. Indian Journal of Medical and Paediatric Oncology, 2018, 39, 493.	0.1	0
269	Toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin ineligible head and neck cancer patients Journal of Clinical Oncology, 2018, 36, e18022-e18022.	0.8	0
270	Long-term survival outcomes of technically unresectable carcinoma maxilla postinduction chemotherapy. South Asian Journal of Cancer, 2018, 07, 213-214.	0.2	0

#	Article	IF	CITATIONS
271	QOL assessment in head and neck cancer patients undergoing neoadjuvant chemotherapy and its impact on overall survival Journal of Clinical Oncology, 2019, 37, e17519-e17519.	0.8	0
272	Stereotactic body radiation therapy for medically inoperable early-stage lung cancer: Tata Memorial Hospital perspective and practice recommendations. Indian Journal of Cancer, 2020, 57, 18.	0.2	0
273	Second malignancy post-chemoradiation in head and neck cancer patients Journal of Clinical Oncology, 2020, 38, e18525-e18525.	0.8	0
274	Indication of adjuvant chemoradiation post neoadjuvant chemotherapy in very locally advanced borderline resectable head and neck cancer Journal of Clinical Oncology, 2020, 38, e18505-e18505.	0.8	0
275	Quality of life in patients with locally advanced head and neck cancer undergoing chemoradiation with once-a-week versus once-every-three-weeks cisplatin Journal of Clinical Oncology, 2020, 38, 12092-12092.	0.8	0
276	Leptomeningeal metastasis from non-small cell lung cancer- outcomes from a tertiary care center Journal of Clinical Oncology, 2020, 38, e14508-e14508.	0.8	0
277	Association of immune-related adverse effects and survival in responders treated with immune checkpoint inhibitors Journal of Clinical Oncology, 2020, 38, e15172-e15172.	0.8	0
278	Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral cavity squamous cell carcinoma (SCC) Journal of Clinical Oncology, 2020, 38, e18550-e18550.	0.8	0
279	A phase III randomized clinical trial of diclofenac versus tramadol for mucositis-related pain in head and neck cancer patients undergoing concurrent chemoradiation Journal of Clinical Oncology, 2020, 38, e24124-e24124.	0.8	0
280	Hypothyroidism and its impact on outcomes in head and neck cancer Journal of Clinical Oncology, 2020, 38, e24066-e24066.	0.8	0
281	Long-term outcomes of locally advanced and borderline resectable esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation treated with neoadjuvant chemotherapy Journal of Clinical Oncology, 2020, 38, e18507-e18507.	0.8	0
282	Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors. Indian Journal of Surgical Oncology, 2022, 13, 81-86.	0.3	0
283	Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience. South Asian Journal of Cancer, 2020, 09, 67-68.	0.2	0
284	Lymphopenia during chemoradiation-foe or friend. Ecancermedicalscience, 2020, 14, 1109.	0.6	0
285	Multidisciplinary brain metastasis clinic: is it effective and worthwhile?. Ecancermedicalscience, 2020, 14, 1136.	0.6	0
286	Radiation necrosis of the bone, cartilage or cervical soft-tissues following definitive high-precision radio(chemo)therapy for head-neck cancer: uncommon and under-reported phenomenon. Journal of Laryngology and Otology, 2021, , 1-22.	0.4	0
287	Hypomagnesemia in patients with locally advanced head and neck cancer treated weekly cisplatin-incidence and impact on outcomes. Oral Oncology, 2022, 125, 105709.	0.8	0
288	Hepatocellular carcinoma presenting as double head. Indian Journal of Gastroenterology, 2006, 25, 255.	0.7	0

#	Article	IF	CITATIONS
289	Metachronous gastric diffuse large B-cell lymphoma and adenocarcinoma. Indian Journal of Gastroenterology, 2006, 25, 261-2.	0.7	0
290	Outcomes of surgical versus non-surgical treatment of resectable T4a laryngeal and hypopharyngeal carcinoma. Journal of Laryngology and Otology, 2022, , 1-24.	0.4	0
291	Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients. Oral Oncology, 2022, 130, 105908.	0.8	О
292	Five years survival outcomes of head and neck cancer patients treated with palliative metronomic chemotherapy Journal of Clinical Oncology, 2022, 40, e18009-e18009.	0.8	0
293	Phase 3 randomized study for evaluation of physician's choice treatment and triple metronomic as second-line therapy in head and neck cancer Journal of Clinical Oncology, 2022, 40, TPS6106-TPS6106.	0.8	0